Journal Scans
Risk of Venous and Arterial Thromboembolic Events Associated With Anti-EGFR Agents: A Meta-Analysis of Randomized Clinical Trials
Anti-EGFRs Increase Risk of Venous Thromboembolism Events
F Petrelli, M Cabiddu, K Borgonovo, S Barni
20120011
2012 Jan 11
Ann Oncol
Risk of Venous and Arterial Thromboembolic Events Associated With Anti-EGFR Agents: A Meta-Analysis of Randomized Clinical Trials
Ann Oncol. 2012 Jan 11;[Epub Ahead of Print], F Petrelli, M Cabiddu, K Borgonovo, S Barni
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
Venous and arterial thromboembolism events (VTEs and ATEs) are common in patients with cancer and are a frequent cause of mortality in these patients. Antiangiogenic agents that target vascular endothelial growth factor receptor (VEGFR), such as sunitinib, sorafenib, and bevacizumab, are associated with increased risk of VTEs and ATEs. Other drugs target the epidermal growth factor receptor (EGFR), such as the monoclonal antibodies cetuximab and panitumumab, and the oral tyrosine kinase inhibitors...
